14. A kit comprising the binding molecule as defined in claim 1.

15. The binding molecule according to claim 1, wherein the first binding domain comprises a VH region comprising

(a) CDR-H1 as depicted in SEQ ID NO: 1, SEQ ID NO: 161, or SEQ ID NO: 311;

(b) CDR-H2 as depicted in SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 162, SEQ ID NO: 212, SEQ ID NO: 312, SEQ ID NO: 322, SEQ ID NO: 352, SEQ ID NO: 362, SEQ ID NO: 582, SEQ ID NO: 622, or SEQ ID NO: 752; and

(c) CDR-H3 as depicted in SEQ ID NO: 3, SEQ ID NO: 163, SEQ ID NO: 313, SEQ ID NO: 323, or SEQ ID NO: 623; and

a VL region comprising

(a) CDR-L1 as depicted in SEQ ID NO: 4, SEQ ID NO: 164, SEQ ID NO: 314, SEQ ID NO: 624, SEQ ID NO: 774, SEQ ID NO: 974, or SEQ ID NO: 994;

(b) CDR-L2 as depicted in SEQ ID NO: 5, SEQ ID NO: 165, SEQ ID NO: 315, or SEQ ID NO: 625; and

(c) CDR-L3 as depicted in SEQ ID NO: 6, SEQ ID NO: 166, SEQ ID NO: 176, SEQ ID NO: 316, SEQ ID NO: 626, SEQ ID NO: 656, SEQ ID NO: 676, SEQ ID NO: 776, SEQ ID NO: 816, SEQ ID NO: 966, or SEQ ID NO: 996.

16. A nucleic acid ~~sequence~~ molecule encoding a binding molecule as defined in any one of claims 1 to 12 and 15

17. A vector comprising a nucleic acid ~~sequence~~ molecule as defined in claim 16.

18. A host cell transformed or transfected with the nucleic acid ~~sequence~~ molecule as defined in claim 16 or with the vector as defined in claim 17.

19. A process for the production of a binding molecule according to any one of claims 1 to 12 and 15, said process comprising culturing a host cell as defined in claim 18 under conditions allowing the expression of the binding molecule as defined in any one of claims 1 to 12 and 15 and recovering the produced binding molecule from the culture.

20. A pharmaceutical composition comprising a binding molecule according to any one of claims 1 to 12 and 15, or produced according to the process of claim 19.

21. The binding molecule according to any one of claims 1 to 12 and 15, or produced according to the process of claim 19 for use in the prevention, treatment or amelioration of a disease selected from the group consisting of plasma cell disorders, other B cell disorders that correlate with BCMA expression and autoimmune diseases.

22. The binding molecule according to claim 21, wherein the plasma cell disorder is selected from the group consisting of multiple myeloma, plasmacytoma, plasma cell leukemia, macroglobulinemia, amyloidosis, Waldenstrom's macroglobulinemia , solitary bone plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain diseases, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

23. The binding molecule according to claim 21, wherein the autoimmune disease is systemic lupus erythematosus.

24 Use of the binding molecule according to any one of claims 1 to 12 and 15, or produced according to the process of claim 19 in the preparation of a medicament for the treatment or amelioration of a disease selected from the group consisting of plasma cell disorders, other B cell disorders that correlate with BCMA expression ~~and autoimmune diseases~~.

25. The use according to claim 24, wherein the plasma cell disorder is selected from the group consisting of multiple myeloma, plasmacytoma, plasma cell leukemia, macroglobulinemia, amyloidosis, Waldenstrom's macroglobulinemia , solitary bone plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain diseases, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

~~26. The use according to claim 24, wherein the autoimmune disease is systemic lupus erythematosus.~~

276. A kit comprising a binding molecule as defined in any one of claims 1 to 12 and 15, a nucleic acid ~~sequence~~ molecule as defined in claim 16, a vector as defined in claim 17, and/or a host cell as defined in claim 18.